Macitent 10mg Tablet contains Macitentan, a potent endothelin receptor antagonist used primarily in the management of pulmonary arterial hypertension (PAH). Macitentan functions by selectively blocking endothelin receptors ETA and ETB, which play a critical role in vasoconstriction and vascular remodeling associated with PAH. By inhibiting these receptors, Macitentan promotes vasodilation and reduces pulmonary vascular resistance, thereby improving exercise capacity and delaying disease progression. This medication is indicated for patients diagnosed with WHO Group 1 PAH to improve symptoms and reduce the risk of clinical worsening. Macitent 10mg is administered orally, typically once daily, and should be used under strict medical supervision. Prior to initiation, liver function tests and hemoglobin levels should be assessed, as Macitentan may cause hepatotoxicity and anemia. Common adverse effects include headache, nasal congestion, anemia, and elevated liver enzymes. It is contraindicated in pregnancy due to teratogenic potential; effective contraception is mandatory for women of childbearing potential during treatment and for a specified period after discontinuation. Patients should be monitored regularly for signs of liver impairment and anemia. Macitent 10mg offers a valuable therapeutic option in the comprehensive management of PAH, improving patient outcomes and quality of life.